IRF5 and systemic lupus erythematosus: The therapeutic effects on the Lyn-deficient mouse SLE model obtained by the genetic approach (deletion of Irf5 after the disease onset) next prompted us to develop IRF5 inhibitors as novel therapeutics for SLE.